Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 144

1.

Semiquantitative GATA-3 immunoreactivity in breast, bladder, gynecologic tract, and other cytokeratin 7-positive carcinomas.

Clark BZ, Beriwal S, Dabbs DJ, Bhargava R.

Am J Clin Pathol. 2014 Jul;142(1):64-71. doi: 10.1309/AJCP8H2VBDSCIOBF.

PMID:
24926087
[PubMed - indexed for MEDLINE]
2.

Interpretation of human epidermal growth factor receptor 2 (HER2) in situ hybridization assays using 2013 update of American Society of Clinical Oncology/College of American Pathologists HER2 Guidelines.

Bhargava R, Dabbs DJ.

J Clin Oncol. 2014 Jun 10;32(17):1855. doi: 10.1200/JCO.2013.53.9213. Epub 2014 Apr 28. No abstract available.

PMID:
24778404
[PubMed - in process]
3.

Low ER+ breast cancer: Is this a distinct group?

Gloyeske NC, Dabbs DJ, Bhargava R.

Am J Clin Pathol. 2014 May;141(5):697-701. doi: 10.1309/AJCP34CYSATWFDPQ.

PMID:
24713741
[PubMed - indexed for MEDLINE]
4.

Invasive lobular carcinoma cell lines are characterized by unique estrogen-mediated gene expression patterns and altered tamoxifen response.

Sikora MJ, Cooper KL, Bahreini A, Luthra S, Wang G, Chandran UR, Davidson NE, Dabbs DJ, Welm AL, Oesterreich S.

Cancer Res. 2014 Mar 1;74(5):1463-74. doi: 10.1158/0008-5472.CAN-13-2779. Epub 2014 Jan 14.

PMID:
24425047
[PubMed - indexed for MEDLINE]
5.

Bright-field HER2 dual in situ hybridization (DISH) assay vs fluorescence in situ hybridization (FISH): focused study of immunohistochemical 2+ cases.

Gao FF, Dabbs DJ, Cooper KL, Bhargava R.

Am J Clin Pathol. 2014 Jan;141(1):102-10. doi: 10.1309/AJCP6CXS8OSRHXIR.

PMID:
24343743
[PubMed - indexed for MEDLINE]
6.

Lobular neoplasia of the breast revisited with emphasis on the role of E-cadherin immunohistochemistry.

Dabbs DJ, Schnitt SJ, Geyer FC, Weigelt B, Baehner FL, Decker T, Eusebi V, Fox SB, Ichihara S, Lakhani SR, Palacios J, Rakha E, Richardson AL, Schmitt FC, Tan PH, Tse GM, Vincent-Salomon A, Ellis IO, Badve S, Reis-Filho JS.

Am J Surg Pathol. 2013 Jul;37(7):e1-11. doi: 10.1097/PAS.0b013e3182918a2b. Review.

PMID:
23759937
[PubMed - indexed for MEDLINE]
7.

Prediction of the Oncotype DX recurrence score: use of pathology-generated equations derived by linear regression analysis.

Klein ME, Dabbs DJ, Shuai Y, Brufsky AM, Jankowitz R, Puhalla SL, Bhargava R.

Mod Pathol. 2013 May;26(5):658-64. doi: 10.1038/modpathol.2013.36. Epub 2013 Mar 15.

PMID:
23503643
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Cancer of unknown primary origin: using ancillary techniques with caution.

Bhargava R, Dabbs DJ.

J Clin Oncol. 2013 Apr 10;31(11):1478-9. doi: 10.1200/JCO.2012.46.9056. Epub 2013 Feb 25. No abstract available.

PMID:
23439751
[PubMed - indexed for MEDLINE]
Free Article
9.

Immunohistochemistry and HPV in situ hybridization in pathologic distinction between endocervical and endometrial adenocarcinoma: a comparative tissue microarray study of 76 tumors.

Jones MW, Onisko A, Dabbs DJ, Elishaev E, Chiosea S, Bhargava R.

Int J Gynecol Cancer. 2013 Feb;23(2):380-4. doi: 10.1097/IGC.0b013e31825cc8ee.

PMID:
23318908
[PubMed - indexed for MEDLINE]
10.

Invasive lobular carcinoma of the breast: patient response to systemic endocrine therapy and hormone response in model systems.

Sikora MJ, Jankowitz RC, Dabbs DJ, Oesterreich S.

Steroids. 2013 Jun;78(6):568-75. doi: 10.1016/j.steroids.2012.11.002. Epub 2012 Nov 21. Review.

PMID:
23178159
[PubMed - in process]
11.

Morphologic features do not influence response to trastuzumab-containing neoadjuvant chemotherapy in HER2-positive breast cancer.

Li X, Kanbour-Shakir A, Dabbs DJ, Bhargava R.

Appl Immunohistochem Mol Morphol. 2013 Oct;21(5):420-5. doi: 10.1097/PAI.0b013e318273c1cc.

PMID:
23165332
[PubMed - indexed for MEDLINE]
12.

Interobserver agreement among pathologists for semiquantitative hormone receptor scoring in breast carcinoma.

Cohen DA, Dabbs DJ, Cooper KL, Amin M, Jones TE, Jones MW, Chivukula M, Trucco GA, Bhargava R.

Am J Clin Pathol. 2012 Dec;138(6):796-802. doi: 10.1309/AJCP6DKRND5CKVDD.

PMID:
23161712
[PubMed - indexed for MEDLINE]
Free Article
13.

Commonly encountered dilemmas in breast cancer reporting and staging.

Adams AL, Dabbs DJ.

Semin Diagn Pathol. 2012 Aug;29(3):109-15. doi: 10.1053/j.semdp.2011.08.003. Review.

PMID:
23062418
[PubMed - indexed for MEDLINE]
14.

Impact of progesterone receptor semiquantitative immunohistochemical result on Oncotype DX recurrence score: a quality assurance study of 1074 cases.

Clark BZ, Dabbs DJ, Cooper KL, Bhargava R.

Appl Immunohistochem Mol Morphol. 2013 Jul;21(4):287-91. doi: 10.1097/PAI.0b013e31826f80c9.

PMID:
23060300
[PubMed - indexed for MEDLINE]
15.

A validation study of quantum dot multispectral imaging to evaluate hormone receptor status in ductal carcinoma in situ of the breast.

Yu J, Monaco SE, Onisko A, Bhargava R, Dabbs DJ, Cieply KM, Fine JL.

Hum Pathol. 2013 Mar;44(3):394-401. doi: 10.1016/j.humpath.2012.06.002. Epub 2012 Oct 3.

PMID:
23039940
[PubMed - indexed for MEDLINE]
16.

The effect of 96-hour formalin fixation on the immunohistochemical evaluation of estrogen receptor, progesterone receptor, and HER2 expression in invasive breast carcinoma.

Yildiz-Aktas IZ, Dabbs DJ, Cooper KL, Chivukula M, McManus K, Bhargava R.

Am J Clin Pathol. 2012 May;137(5):691-8. doi: 10.1309/AJCPQRAG67GJRPMT.

PMID:
22523206
[PubMed - indexed for MEDLINE]
Free Article
17.

The effect of cold ischemic time on the immunohistochemical evaluation of estrogen receptor, progesterone receptor, and HER2 expression in invasive breast carcinoma.

Yildiz-Aktas IZ, Dabbs DJ, Bhargava R.

Mod Pathol. 2012 Aug;25(8):1098-105. doi: 10.1038/modpathol.2012.59. Epub 2012 Mar 30.

PMID:
22460807
[PubMed - indexed for MEDLINE]
Free Article
18.

Predictors of pathologic complete response after standard neoadjuvant chemotherapy in triple-negative breast carcinoma.

Kraus JA, Beriwal S, Dabbs DJ, Ahrendt GM, McGuire KP, Johnson RR, Badve P, Puhalla SL, Bhargava R.

Appl Immunohistochem Mol Morphol. 2012 Jul;20(4):334-9. doi: 10.1097/PAI.0b013e31823f4663.

PMID:
22417856
[PubMed - indexed for MEDLINE]
19.

Semi-quantitative immunohistochemical assay versus oncotype DX(®) qRT-PCR assay for estrogen and progesterone receptors: an independent quality assurance study.

Kraus JA, Dabbs DJ, Beriwal S, Bhargava R.

Mod Pathol. 2012 Jun;25(6):869-76. doi: 10.1038/modpathol.2011.219. Epub 2012 Feb 3.

PMID:
22301704
[PubMed - indexed for MEDLINE]
Free Article
20.

Oncotype DX test on unequivocally HER2-positive cases: potential for harm.

Bhargava R, Dabbs DJ.

J Clin Oncol. 2012 Feb 10;30(5):570-1. doi: 10.1200/JCO.2011.40.1323. Epub 2012 Jan 9. No abstract available.

PMID:
22231038
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk